Aeolus Announces Fiscal Year 2013 Financial Results
December 23, 2013 08:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Dec 23, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus Files Application for New Patent on AEOL 10150
December 05, 2013 11:14 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Dec 5, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Filing covers synthesis, formulation and pharmaceutical composition
...
Aeolus' AEOl 10150 Significantly Improves Survival and Protects Lungs in Mice Exposed to Lethal Radiation
October 29, 2013 08:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Oct 29, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Optimal dose of AEOL 10150 improved survival by four times over untreated...
BARDA Exercises $6.0MM in Additional Contract Funding for Development of AEOL-10150 as Treatment for Acute Radiation Syndrome
September 17, 2013 13:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Sep 17, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
BARDA exercise options valued at $6.0 million effective September 16, 2013...
Aeolus' AEOL 10150 Subject of $4.3 Million US Government Award for Protection Against Nerve Agents; Data Shows Drug Significantly Improves Survival in Animals Following Exposure to Pilocarpine, a Nerve Agent Surrogate for Soman and Sarin Gas
September 11, 2013 12:20 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Sep 11, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
National Institutes of Health - National Institute of Neurological...
Aeolus Announces Third Quarter Fiscal Year 2013 Financial Results
August 14, 2013 16:30 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Aug 14, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus' AEOL 10150 Significantly Improves Survival From Nitrogen Mustard Exposure to Skin in Animals
July 02, 2013 08:00 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jul 2, 2013) - Aeolus Pharmaceuticals (OTCQB: AOLS)
Data presented at 6th Annual NIH CounterACT Network Research Symposium
...
Aeolus' AEOL 10150 Significantly Improves Survival in Animals Exposed to Mustard Gas
June 26, 2013 14:02 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jun 26, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS)
Data presented at 7th Annual NIH CounterACT Network Research...
Aeolus Strengthens Board of Directors With Oncology, Government Contracting and Financial Industry Veterans
May 17, 2013 14:19 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - May 17, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of novel...
Aeolus Pharmaceuticals Announces Second Quarter Fiscal Year 2013 Financial Results
May 15, 2013 14:38 ET
|
Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - May 15, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of novel...